<div id="readability-page-1">Sarepta Therapeutics Inc. ( SRPT ) on Monday released topline three-year functional results from Part 1-treated patients in the EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory individuals with Duchenne muscular dystrophy. Three years after treatment, patients who received Elevidys in Part 1 of EMBARK demonstrated statistically significant, clinically meaningful, and durable efficacy across all key motor function measures, North Star Ambulatory Assessment (NSAA), Time to Rise (TTR), and 10-meter walk/run (10MWR), when compared to a pre-specified propensity-weighted untreated external control group. The mean NSAA score remained above baseline at Year 3 for the Elevidys-treated group (n=52) while the EC group (n=73) continued to show the expected age-related decline below their baseline score. The Elevidys group showed a 73% slowing of disease progression as measured by TTR and 70% slowing of disease progression as measured by 10MWR when compared to the control group. Patients treated with Elevidys in Part 1 maintained significantly higher levels of motor function three years after treatment compared to the control group. No new treatment-related safety signals were observed. Analysis of the three-year data is ongoing and includes functional results from crossover-treated patients two years after treatment. Elevidys is the only approved gene therapy for Duchenne, and to date, the drug has been administered to over 1,200 patients globally in clinical and real-world settings. Elevidys is available as appropriate to ambulatory individuals ages four and above, per an updated FDA label announced in November 2025. <h2>Roche Collaboration And Expanded Patient Studies</h2> As part of a collaboration agreement signed in 2019, Sarepta is working with Roche Holdings AG (OTC:RHHBY) to transform the future for the Duchenne community, with the goal of enabling those living with the disease to maintain and protect their muscle function. Sarepta handles U.S. regulatory approval, manufacturing, and commercialization of Elevidys, while Roche manages regulatory approvals and distribution globally outside the U.S., with Chugai Pharmaceuticals leading commercialization in Japan. In November 2025, the U.S. Food and Drug Administration (FDA) approved dosing in Sarepta’s Cohort 8 of ENDEAVOR (Study 9001-103). The purpose of Cohort 8 is to evaluate the use of an enhanced immunosuppressive regimen as part of treatment with Elevidys for non-ambulant (patients who cannot walk) individuals with Duchenne muscular dystrophy. <h2>Recent Financial Performance</h2> Earlier in January, Sarepta reported a preliminary fourth-quarter product revenue of $369.6 million and $1.86 billion for full-year 2025. Fourth quarter and full-year 2025 net product revenue for Elevidys reached $110.4 million and $898.7 million, respectively. SRPT Price Action: Sarepta Therapeutics ( SRPT ) shares were up 5.06% at $22.20 during premarket trading on Monday, according to Benzinga Pro data. Photo via Shutterstock</div>

Sarepta Therapeutics Inc. 宣佈其針對杜氏肌營養不良症的 Elevidys 第三階段 EMBARK 研究的三年積極結果。接受 Elevidys 治療的患者在運動功能上顯示出顯著改善，與對照組相比，疾病進展速度減緩了 73%。該藥物是唯一獲得批准的杜氏基因療法，已被應用於超過 1,200 名患者。Sarepta 報告稱，2025 年第四季度產品收入為 3.696 億美元，全年收入為 18.6 億美元。股價在盤前交易中上漲 5.06%，至 22.20 美元

Sarepta Says Elevidys Slows Duchenne Progression After Three Years

fidelity

醫療業 ETF - Vanguard

美國制藥 ETF - iShares

Tradr 2X Long SRPT Daily ETF

標普全球醫療股指數 ETF - iShares

Invesco Nasdaq Biotechnology ETF

醫藥突破 ETF - ALPS

醫療業 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

標普生物技術 ETF - SPDR

Sarepta醫療

基因改革 ETF - ARK

紐交所高增長板生物技術指數 ETF - First Trust

納斯達克生物科技指數 ETF - iShares Nasdaq

2 倍做多納斯達克生物技術 ETF - ProShares

生物科技 ETF - VanEck Vectors

Sarepta 表示，Elevidys 在三年後減緩了杜氏肌營養不良症的進展